PRESS RELEASE published on 08/04/2025 at 07:00, 1 year 1 month ago Inside Information / Other news releases Innate Pharma discloses total shares outstanding and voting rights as of August 1, 2025. The company is a global biotech developing immunotherapies for cancer patients Voting Rights Biotechnology Immunotherapy Innate Pharma Shares Outstanding
BRIEF published on 07/04/2025 at 07:05, 1 year 2 months ago Innate Pharma Announces Share and Voting Rights Update Voting Rights Shares Euronext Nasdaq Innate Pharma
PRESS RELEASE published on 07/04/2025 at 07:00, 1 year 2 months ago Inside Information / Other news releases Innate Pharma discloses number of shares and voting rights as of July 3, 2025, in accordance with French regulations. Total shares: 92,183,523. Total voting rights: 92,962,943 (theoretical) and 92,944,368 (exercisable) Voting Rights Shares French Regulations Financial Disclosure Innate Pharma
BRIEF published on 06/17/2025 at 07:05, 1 year 3 months ago Innate Pharma to Participate in Key Investor Conferences Biotechnology Investor Conferences Healthcare Immunotherapy Innate Pharma
PRESS RELEASE published on 06/17/2025 at 07:00, 1 year 3 months ago Inside Information / Other news releases Innate Pharma to participate in H.C. Wainwright and Wolfe Research healthcare conferences showcasing their innovative immunotherapy approaches. Global biotech company expanding portfolio Biotechnology Immunotherapy Clinical-stage Innate Pharma Healthcare Conferences
BRIEF published on 06/13/2025 at 07:05, 1 year 3 months ago Innate Pharma's IPH6501 Shows Potential in Lymphoma Treatment Innate Pharma Preclinical Results IPH6501 Lymphoma R-CHOP
PRESS RELEASE published on 06/13/2025 at 07:00, 1 year 3 months ago Inside Information / Other news releases Innate Pharma highlights preclinical antitumor activity of IPH6501 in DLBCL and FL at the 2025 EHA Congress, presenting potent efficacy in in vitro and in vivo models with R-CHOP combination Preclinical Data EHA Congress Innate Pharma Antitumor Activity IPH6501
BRIEF published on 05/13/2025 at 07:05, 1 year 4 months ago Innate Pharma Reports First Quarter 2025 Results Financial Results Clinical Trials Innate Pharma Sanofi Investment Lacutamab FDA
PRESS RELEASE published on 05/13/2025 at 07:00, 1 year 4 months ago Inside Information / News release on accounts, results Innate Pharma reports Q1 2025 business update with €15 million investment by Sanofi, FDA Breakthrough Therapy Designation for lacutamab, and cash position of €72.5 million FDA Financial Results Sanofi Innate Pharma Q1 2025
BRIEF published on 05/02/2025 at 15:27, 1 year 4 months ago Sanofi increases its stake in Innate Pharma Capital Actions Crossing Thresholds Sanofi Innate Pharma
Published on 09/21/2026 at 15:45, 17 minutes ago Datavault AI and Cutting-Edge Sports Management Announce Dream Bowl XV at AT&T Stadium and Launch First-of-Its-Kind Bowl Combine
Published on 09/21/2026 at 14:20, 1 hour 42 minutes ago Doctor's Choice(R) Clinically-Proven Scrubs Launching on Amazon Canada
Published on 09/21/2026 at 14:05, 1 hour 57 minutes ago Winners of this Year's Semmelweis-Richter International Journalism Award Announced
Published on 09/21/2026 at 14:00, 2 hours 2 minutes ago Dateline Files Motion to Resume Operations at Colosseum
Published on 09/21/2026 at 13:45, 2 hours 17 minutes ago Nine Mile Metals DDH WD-26-11 Intersects 2 High Grade VMS Zones Over 27.6M Including 3.08% CU-EQ Over 10.70M, 3.27% CU-EQ Over 9.30M and 4.30% CU-EQ Over 5.0M
Published on 09/21/2026 at 15:35, 26 minutes ago Form 8.3 - The Vanguard Group, Inc.: Permanent TSB Group Holdings plc
Published on 09/21/2026 at 15:35, 27 minutes ago Hg extends collaboration with Anthropic to bring agentic AI capabilities across the portfolio
Published on 09/21/2026 at 07:00, 9 hours 2 minutes ago Peugeot Invest takes a stake in Mérieux NutriSciences
Published on 09/18/2026 at 18:34, 2 days 21 hours ago Disclosure of transactions in own shares from September 14 to September 18, 2026
Published on 09/17/2026 at 17:40, 3 days 22 hours ago Eiffage wins a second contract, as part of the NSORe joint venture, for an offshore converter station in Germany
